MHK
49
4
XRAY
28
2
PFE
23
7
M
37
12
EBAY
47
4
CAH
48
-5
NVDA
56
-4
LRCX
43
-2
FE
50
-2
DE
63
3
KEY
46
3
AAP
24
6
HPQ
63
6
CMG
72
5
LNC
39
3
AN
58
4
SWK
64
5
STZ
54
-3
HD
57
2
DVN
21
3
MHK
49
4
XRAY
28
2
PFE
23
7
M
37
12
EBAY
47
4
CAH
48
-5
NVDA
56
-4
LRCX
43
-2
FE
50
-2
DE
63
3
KEY
46
3
AAP
24
6
HPQ
63
6
CMG
72
5
LNC
39
3
AN
58
4
SWK
64
5
STZ
54
-3
HD
57
2
DVN
21
3
Financhill
Back

Kazia Therapeutics 10K Form

Buy
67

KZIA
Kazia Therapeutics

Last Price:
5.77
Seasonality Move:
17.72%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2006-11-07 10Q KZIA/Kazia Therapeutics Quarterly

Receive KZIA News And Ratings

See the #1 stock for the next 7 days that we like better than KZIA

KZIA Financial Statistics

Sales & Book Value

Annual Sales: $1.51M
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $-2.01
Price / Book: 0

Profitability

EPS (TTM): -6.66830
Net Income (TTM): $-17.58M
Gross Margin: $1.58M
Return on Equity: -1083.16%
Return on Assets: -106.28%

Kazia Therapeutics Earnings Forecast

Key Kazia Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 12 years for KZIA is 100.00%.
  • The Selling, General & Administrative Expenses for KZIA have been equal to 587.65% of Gross Profit Margin.
  • The Research & Development expenses have been 753.03% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • Per Share Earnings over the last 26 years have been positive in 14 years.

Kazia Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: KZIA
CUSIP: 48669G
Website: kaziatherapeutics.com

Debt

Debt-to-Equity Ratio: -0.06
Current Ratio: 0.24
Quick Ratio: 0.07

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

KZIA Technical Analysis vs Fundamental Analysis

Buy
67
Kazia Therapeutics (KZIA) is a Buy

Is Kazia Therapeutics a Buy or a Sell?